4D Medicine EIS

During surgery, implanting supports like plates, screws and meshes can greatly improve patient outcomes. For example, if a ligament is torn, a screw can help hold a graft in place whilst the injury heals.

Increasingly, these devices tend to be made from bio-absorbable polymers – meant to eventually break down and be absorbed by the body, without the need to be surgically removed. However, traditional bio-absorbable polymers have shortcomings: they can degrade unpredictably and release acidic byproducts – this can result in inflammation, sub-optimal healing and pain for the patient.

After more than 15 years’ academic research and development, 4D Medicine Limited (‘4D Medicine’ or ‘the Company’) has developed a biodegradable polymer platform to overcome these issues. Its patented 4Degra® polymer reportedly offers improved biocompatibility and controlled degradation for better patient healing (read more about the technology below).

4Degra® can be used to 3D-print highly detailed, custom-designed medical devices that are difficult to produce with conventional polymers.

Management estimates its addressable annual global market is $1 billion for bio-absorbable biomaterials, and $6 billion for bio-absorbable medical devices.

4D Medicine spun out from the Universities of Warwick and Birmingham. In 2020, it received investment from SFC Capital (manager of the Startup Funding Club SEIS and EIS funds), DSW Ventures and Mercia Asset Management, which it used to further develop the 4Degra® platform.

The Company holds the rights to the five patent applications – two have been granted in the US. It has already attracted interest: a FTSE 250 company made an acquisition offer of c.£38 million in 2023, contingent on the Company achieving certain milestones. 4D Medicine declined this, believing it could achieve a higher valuation after fully developing its suite of 4Degra® materials.

In 2024, 4D Medicine launched a £7.4 million Series A round. The first tranche led by Oshen Holdings SA closed in April 2024 raising £3.4 million. A further tranche led by Norcliffe Capital raised £1.1 million in June 2025. Oshen and Norcliffe are specialist investors with a biotech/medtech focus.

The Company is now seeking to raise the remaining £2.9 million under EIS at a pre-money valuation of £17.1 million (£101.25 per share). Norcliffe Capital has committed £1.2m and SFC Capital £200k. Wealth Club has an exclusive allocation of £500k – the minimum investment is £20,250.

SFC Capital believes the investment could potentially deliver a return in the region of 10.5x (mid case) before EIS tax relief but after fees in eight to 10 years – high risk and not guaranteed.

SFC Capital has participated in every funding round to date. The Company is now one of the 5 largest investments in SFC's portfolio of 500+ companies and one of the most promising, in the manager's view. 

Please carefully read all investment documents prepared by the Company and SFC to form your own view.

4D Medicine’s 4Degra® is a patented bio-absorbable polymer designed for 3D-printing highly detailed customised implants – quickly, precisely and cost-effectively. It can be used to produce complex one-offs, including at nano and micro scale – this would be otherwise difficult or prohibitively expensive using more traditional manufacturing techniques.

The polymer has shape memory properties: for example, a printed implant can be compressed and inserted by a surgeon through a narrow incision, and then the body’s own heat helps it regain its original shape – minimising invasive surgery.

4Degra® claims several further advantages over existing technology.

The Company’s tests have shown 4Degra® is more biocompatible – and more conducive to tissue regeneration – compared to benchmark commonly-used implant polymers.

4Degra® also appears to biodegrade in a more benign way and at a pace that better allows surrounding tissue to adapt. Unlike implant polymers that degrade all at once, 4Degra® degrades steadily from the outside in – a characteristic described as “controlled surface degradation”. This can prevent rapid loss of structural integrity and enables gradual, predictable absorption of the biodegradation by-products. Moreover, the speed at which 4Degra® degrades can be tuned to match the surrounding tissue’s speed of growth – this would differ between, for example, soft tissue and bone.

Leveraging its 4Degra® biomaterials platform, 4D Medicine is developing a suite of products – including medical devices such as bio-absorbable orthopaedic screws and nerve repair supports, and a line of injectable dermal filler (treatment injected under the skin to add volume) that has aesthetic applications particularly in the Chinese market.

This is a single company offer with no diversification. It involves investing in an early-stage business, which is by nature high risk and prone to failure. There is a risk that the capital raised may not be sufficient to achieve the Company’s objectives. You could lose all the amount you invest.

Like all investments available through Wealth Club, it is only for experienced investors happy to make their own investment decisions without advice.

There is no ready market for unlisted EIS shares: they are illiquid and hard to sell and value. There will need to be an exit for you to receive a realised return on your investment. Exits are likely to take considerably longer than the three-year minimum EIS holding period; equally, an exit within three years could impact tax relief.

To claim tax relief, you will need an EIS3 certificate, normally issued once shares have been allotted. This can take several months: please check the deployment timescales carefully. Tax reliefs depend on company maintaining its EIS-qualifying status. Remember, tax rules can change and benefits depend on circumstances.

Before you invest, please carefully read the Information Memorandum which contains further details on the considerable risks – alongside the Wealth Club Risks and Commitments.

Investors in this round will buy shares in 4D Medicine Limited, the group parent company incorporated in England and Wales.

Wealth Club investors will invest at the same price and on the same terms as the other investors in this round, at a share price of £101.25, equivalent to a fully-diluted pre-money valuation of £17.1 million.

The investment is expected to be EIS-qualifying – not guaranteed. EIS certificates were last issued in June 2025.

Wealth Club Nominees will act as the custodian and administrator of this offer. 

All the services Wealth Club and, where applicable, its subsidiaries provide are governed by the Terms and Conditions of the Wealth Club Services.

Investors will pay no direct initial or ongoing charges to invest, so you should be able to claim EIS tax relief on the full amount you subscribe.

SFC Capital will receive a fundraising fee and an annual fee, which it will share with Wealth Club. Please see the Wealth Club Schedule of Charges for more details.

This financial promotion has been communicated and approved by Wealth Club Ltd on 8 October 2025

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – investments. You should base your investment decision on the offer documents and ensure you have read and fully understand them before investing. The information on this webpage is a marketing communication. It is not advice or a personal or research recommendation to buy any of the investments mentioned, nor does it include any opinion as to the present or future value or price of these investments. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.